Compare
Warby Parker Inc. vs Staar Surgical Co vs Cooper Companies, Inc. vs RxSight, Inc.
| Latest fiscal year | Warby Parker Inc. WRBY | Staar Surgical Co STAA | Cooper Companies, Inc. COO | RxSight, Inc. RXST |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-01-02 | 2025-10-31 | 2025-12-31 |
| Revenue | $871.90M | $239.44M | $4.09B | $134.48M |
| Revenue growth (YoY) | +13.0% | -23.7% | +5.1% | -3.9% |
| Gross margin | 54.0% | 76.2% | 65.5% | 76.6% |
| Operating margin | -0.6% | -38.3% | 16.7% | -35.8% |
| Net margin | 0.2% | -33.6% | 9.2% | -29.0% |
| Net income | $1.64M | -$80.45M | $374.90M | -$38.94M |
| EPS (Diluted) | $0.01 | -$1.62 | $1.87 | -$0.95 |
| Operating cash flow | $110.78M | -$34.23M | $796.10M | -$15.51M |
| Free cash flow | $43.74M | -$40.05M | $433.70M | -$19.34M |
| Cash & equivalents | $286.36M | $153.15M | $110.60M | $19.95M |
| Total assets | $720.92M | $451.68M | $12.39B | $311.81M |
| Total liabilities | $353.19M | $107.49M | $4.16B | $36.13M |
| Shareholders' equity | $367.73M | $344.18M | $8.24B | $275.68M |
| Return on year-end equity | 0.4% | -23.4% | 4.6% | -14.1% |
| Shares outstanding | n/a | 49.40M | 195.90M | 41.24M |
Revenue, most recent five fiscal years
| Fiscal year | Warby Parker Inc. | Staar Surgical Co | Cooper Companies, Inc. | RxSight, Inc. |
|---|---|---|---|---|
| Latest | $871.90M Ended 2025-12-31 | $239.44M Ended 2026-01-02 | $4.09B Ended 2025-10-31 | $134.48M Ended 2025-12-31 |
| 1 year earlier | $771.32M Ended 2024-12-31 | $313.90M Ended 2024-12-27 | $3.90B Ended 2024-10-31 | $139.93M Ended 2024-12-31 |
| 2 years earlier | $669.76M Ended 2023-12-31 | $322.42M Ended 2023-12-29 | $3.59B Ended 2023-10-31 | $89.08M Ended 2023-12-31 |
| 3 years earlier | $598.11M Ended 2022-12-31 | $239.44M Ended 2022-12-30 | $3.31B Ended 2022-10-31 | $49.01M Ended 2022-12-31 |
| 4 years earlier | $540.80M Ended 2021-12-31 | $230.47M Ended 2021-12-31 | $2.92B Ended 2021-10-31 | $22.59M Ended 2021-12-31 |